Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Change in Receivables (2016 - 2025)

Cardiff Oncology's Change in Receivables history spans 15 years, with the latest figure at -$72000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 146.75% year-over-year to -$72000.0; the TTM value through Dec 2025 reached -$591000.0, down 222.11%, while the annual FY2025 figure was -$591000.0, 222.11% down from the prior year.
  • Change in Receivables for Q4 2025 was -$72000.0 at Cardiff Oncology, up from -$272000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $167000.0 in Q3 2024 and bottomed at -$515000.0 in Q2 2023.
  • The 5-year median for Change in Receivables is $76500.0 (2021), against an average of -$6950.0.
  • The largest annual shift saw Change in Receivables skyrocketed 2133.33% in 2021 before it tumbled 595.19% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $141000.0 in 2021, then dropped by 14.18% to $121000.0 in 2022, then decreased by 25.62% to $90000.0 in 2023, then surged by 71.11% to $154000.0 in 2024, then tumbled by 146.75% to -$72000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Change in Receivables are -$72000.0 (Q4 2025), -$272000.0 (Q3 2025), and $121000.0 (Q2 2025).